Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.

Gianni, Luca; Lladó, Anna; Bianchi, Giulia; Cortes, Javier; Kellokumpu-Lehtinen, Pirkko-Liisa; Cameron, David A; Miles, David; Salvagni, Stefania; Wardley, Andrew; Goeminne, Jean-Charles; Hersberger, Veronica; Baselga, José

Gianni, Luca; Lladó, Anna; Bianchi, Giulia; Cortes, Javier; Kellokumpu-Lehtinen, Pirkko-Liisa; Cameron, David A; Miles, David; Salvagni, Stefania; Wardley, Andrew; Goeminne, Jean-Charles; Hersberger, Veronica; Baselga, José.

Affiliation

Gianni L; Oncologia Medica 1, Istituto Nazionale Tumori, Via Venezian, 1, 20133 Milano, Italy. luca.gianni@istitutotumori.mi.it

J Clin Oncol ; 28(7): 1131-7, 2010 Mar 01.

Article in En | MEDLINE | ID: mdl-20124183

Subject(s)

Antibodies, Monoclonal/therapeutic use; Breast Neoplasms/drug therapy; Receptor, ErbB-2/antagonists & inhibitors; Adult; Aged; Antibodies, Monoclonal/adverse effects; Antibodies, Monoclonal/pharmacokinetics; Antibodies, Monoclonal, Humanized; Breast Neoplasms/pathology; Dimerization; Female; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2/analysis; Ventricular Function, Left/drug effects

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Receptor, ErbB-2 / Antibodies, Monoclonal Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: J Clin Oncol Year: 2010 Document type: Article Affiliation country: Italy Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google